, Volume 33, Issue 1, pp 117–120 | Cite as

Pegfilgrastim-jmdb/MYL-1401H: A Pegfilgrastim Biosimilar

  • Sheridan M. HoyEmail author
Adis Biosimilar Brief


Pegfilgrastim-jmdb/MYL-1401H (FULPHILA™) [hereafter referred to as pegfilgrastim-jmdb] is a biosimilar of the reference pegylated recombinant granulocyte colony-stimulating factor pegfilgrastim. It is approved for use in patients receiving chemotherapy for malignancy to decrease the incidence of infection, as manifested by febrile neutropenia, in the USA and to reduce the duration of neutropenia and the incidence of febrile neutropenia in the EU. Pegfilgrastim-jmdb has similar physicochemical characteristics and functional properties to those of US- and EU-sourced reference pegfilgrastim, and the pharmacodynamic and pharmacokinetic similarity of the agents has also been demonstrated in healthy volunteers. Pegfilgrastim-jmdb demonstrated clinical efficacy equivalent to that of EU-sourced reference pegfilgrastim in patients with newly diagnosed Stage II/III breast cancer receiving neoadjuvant or adjuvant chemotherapy and was generally well tolerated in this patient population. The overall safety profile and immunogenic potential of the two agents was similar. The role of reference pegfilgrastim in the management of chemotherapy-induced neutropenia is well established and pegfilgrastim-jmdb provides an effective biosimilar alternative for patients requiring pegfilgrastim therapy.


Compliance with Ethical Standards


The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of pegfilgrastim-jmdb/MYL-1401H was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit. Sheridan Hoy is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.


  1. 1.
    Mylan GmbH. FULPHILA™ (pegfilgrastim-jmdb) injection, for subcutaneous use: US prescribing information. 2018. Accessed 11 Oct 2018.
  2. 2.
    Mylan S.A.S. Fulphila 6 mg solution for injection in pre-filled syringe: EU summary of product characteristics. 2018. Accessed 12 Dec 2018.
  3. 3.
    Waller CF, Tiessen RG, Lawrence TE, et al. A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim. J Cancer Res Clin Oncol. 2018;144(6):1087–95.CrossRefPubMedGoogle Scholar
  4. 4.
    Sankaran PK, Palanivelu DV, Nair R, et al. Characterization and similarity assessment of a pegfilgrastim biosimilar MYL-1401H. J Clin Oncol. 2018;36(15 Suppl):e19028.CrossRefGoogle Scholar
  5. 5.
    US FDA. Center for Drug Evaluation and Research application number 761075Orig1s000: clinical review(s). 2018. Accessed 12 Nov 2018.
  6. 6.
    Waller C, Blakeley C, Pennella E, et al. Phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H vs EU-Neulasta in the prophylactic treatment of chemotherapy-induced neutropenia. Eur J Cancer. 2017;72(Suppl. 1):S42.CrossRefGoogle Scholar
  7. 7.
    Waller C, Ranganna GM, Pennella E, et al. Comparison of immunogenicity between the proposed pegfilgrastim biosimilar MYL-1401H and reference pegfilgrastim. Blood. 2017;130(Suppl 1):3568.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations